DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Sean Peche - 1 it's - 1 Peche - 1 there's - 1 that's - 1 Eli Lilly - 1 Amgen - 1 Carol Dou - 1
Top related locs:
Hong Kong Novo Europe U.S
Top related orgs:
Novo Nordisk - 1 Ranmore Fund Management - 1 United Laboratories - 1 Pfizer - 1 AstraZeneca - 1 Global Equity Fund - 1 Hong - 1 Hong Kong bourse - 1

Search resuls for: "United Laboratories"


1 mentions found


☆ Beyond Novo: Fund manager likes this under-the-radar pharma stock with a weight loss drug in the works
  + stars: | 2024-10-04 | by ( Amala Balakrishner | In Amala-Balakrishner | ) www.cnbc.com   time to read: +3 min
"Maybe that weight loss product (by United Laboratories) works, maybe it doesn't. United Laboratories' price-to-earnings of 5.8 times is a fraction of the 34.3 times that Novo Nordisk is trading at, Peche added. [United Laboratories] is making smooth progress in R & D and targets to launch Liraglutide in 2024. Their comments follow United Laboratories' "faster than expected earnings" growth in the first half of the year. Analysts' average price target on United Laboratories is 12.95 Hong Kong dollars, giving it 28.2% potential upside.
Persons: Sean Peche, it's, Peche, there's, that's, Eli Lilly, Amgen, Carol Dou, Sunny Chen, UOB Kay Hian, bode Organizations: Novo Nordisk, Ranmore Fund Management, United Laboratories, Pfizer, AstraZeneca, Global Equity Fund, Hong, Hong Kong bourse, HK Locations: Hong Kong, Novo, Europe, U.S
0 next >>
Total: 1